- Trials with a EudraCT protocol (96)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
96 result(s) found for: Nivolumab and NSCLC.
Displaying page 3 of 5.
EudraCT Number: 2016-001835-11 | Sponsor Protocol Number: CA018-001 | Start Date*: 2017-02-01 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer (Master Protocol Revised version 02 dated 27-Jul-2016 + S... | ||||||||||||||||||
Medical condition: Advanced Non-Small Cell Lung Cancer (NSCLC) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) AT (Completed) FR (Completed) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-003454-83 | Sponsor Protocol Number: 2019IN01 | Start Date*: 2019-12-20 | ||||||||||||||||
Sponsor Name:Amsterdam UMC, VU University Medical Center | ||||||||||||||||||
Full Title: Ipilimumab plus Nivolumab and ChemoRadiotherapy followed by Surgery in patients with resectable and borderline resectable T3-4N0-1 NSCLC | ||||||||||||||||||
Medical condition: locally advanced non-small cell lung cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-005106-35 | Sponsor Protocol Number: INTRUST | Start Date*: 2018-12-21 |
Sponsor Name:Clínica Universidad de Navarra/Universidad de Navarra | ||
Full Title: PHASE I - II STUDY OF INTRATUMORAL URELUMAB COMBINED WITH NIVOLUMAB IN PATIENTS WITH SOLID TUMORS | ||
Medical condition: Advanced solid tumors | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-002540-33 | Sponsor Protocol Number: IFCT-1701 | Start Date*: 2017-12-15 |
Sponsor Name:IFCT | ||
Full Title: A randomized phase 3 trial comparing continuation Nivolumab-Ipilimumab doublet immunotherapy until progression versus observation in treatment-naive patients with PDL1-positive stage IV Non-Small C... | ||
Medical condition: PD-L1 positive stage IV Non Small Cell Lung Cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2016-003030-24 | Sponsor Protocol Number: EDEN-GOIRC-04-2016 | Start Date*: 2017-05-24 | ||||||||||||||||
Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC) | ||||||||||||||||||
Full Title: “An open-label, randomized phase III study of Early switch maintenance vs DElayed second-line Nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-l... | ||||||||||||||||||
Medical condition: Advanced stage (IIIB/IV) squamous non-small cell lung cancer (NSCLC) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000462-11 | Sponsor Protocol Number: CA209-592 | Start Date*: 2018-07-24 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: An Exploratory Study of the Biologic Effects and Biomarkers of Nivolumab in combination with Ipilimumab in Subjects with Treatment-Naive Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC) | ||||||||||||||||||
Medical condition: Treatment-Naive Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) BE (Completed) NL (Completed) ES (Completed) IT (Completed) RO (Ongoing) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-004284-27 | Sponsor Protocol Number: CA043-001 | Start Date*: 2022-01-17 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 1/2 First-in-human Study of BMS-986288 Alone and in Combination with Nivolumab in Advanced Malignant Tumors | |||||||||||||
Medical condition: Advanced solid tumors (squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), cutaneous melanoma, triple-negative breast cancer (TNBC), renal cell carcinoma (RCC)... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004095-31 | Sponsor Protocol Number: ModuLung | Start Date*: 2015-07-13 | |||||||||||||||||||||
Sponsor Name:Freistaat Bayer respresented by University of Regensburg represented by Kaufmännischer Direktor | |||||||||||||||||||||||
Full Title: A prospective phase II, randomized multi-center trial of a combined modularized treatment with metronomic low-dose treosulfan, pioglitazone and clarithromycin versus nivolumab in patients with squ... | |||||||||||||||||||||||
Medical condition: locally advanced or metastatic NSCLC, who have progressed during or following a platinum-containing regimen. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-000262-38 | Sponsor Protocol Number: CA209-77T | Start Date*: 2019-08-23 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolum... | |||||||||||||
Medical condition: Resectable Stage II-IIIB Non-small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) NL (Ongoing) GB (GB - no longer in EU/EEA) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003866-14 | Sponsor Protocol Number: APX005M-002 | Start Date*: 2019-02-28 | ||||||||||||||||
Sponsor Name:Apexigen, Inc. | ||||||||||||||||||
Full Title: A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastati... | ||||||||||||||||||
Medical condition: Non-small Cell Lung Cancer and Metastatic Melanoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) FR (Ongoing) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-004283-65 | Sponsor Protocol Number: CA209-79X | Start Date*: 2020-08-26 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: A Phase 1/2, Randomized Study Evaluating Multiple Nivolumab Combination Therapies in Patients with Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) after Failure of Platinum-Based Chemother... | ||||||||||||||||||
Medical condition: Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) after Failure of Platinum- Based Chemotherapy and Anti-PD-1 (L1) Immunotherapy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) PL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000693-18 | Sponsor Protocol Number: BreakB5/CA209-7WF | Start Date*: 2020-12-07 | |||||||||||
Sponsor Name:University Hospital Regensburg | |||||||||||||
Full Title: Breaking the big Five Barriers of Brain Metastasis (Break B5-BM NSCLC Trial): A prospective phase II, open-label, multi-center trial of combined nivolumab, ipilimumab and bevacizumab together with ... | |||||||||||||
Medical condition: non-squamous non-small-cell lung cancer (NSCLC) metastatic to the brain | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003805-82 | Sponsor Protocol Number: P/2019/451 | Start Date*: 2020-03-05 |
Sponsor Name:CHU de Besançon | ||
Full Title: UCPVax plus Nivolumab versus standard chemotherapy as second line therapy in advanced non-small cell lung cancer : a randomized non-comparative phase II trial | ||
Medical condition: lung cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-005142-29 | Sponsor Protocol Number: UC-0107/1718 | Start Date*: 2018-08-30 |
Sponsor Name:UNICANCER | ||
Full Title: PD-(L)1 iNhibitors with concurrent IRadiation at VAried tumour sites in advanced Non-small cell lung cAncer | ||
Medical condition: Advanced (stage IIIB/IIIC/IV) NSCLC patients eligible for treatment with a PD-1 or PD-L1 antagonist according to the European Marketing Authorisation in a first line or a second line | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002108-15 | Sponsor Protocol Number: CA044-001 | Start Date*: 2018-09-25 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: Phase 1/2 Study of BMS-986310 Administered Alone and in Combination with Nivolumab in Participants with Advanced Solid Tumors | |||||||||||||
Medical condition: Advanced Solid Tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003543-11 | Sponsor Protocol Number: 16-214-02 | Start Date*: 2017-07-10 | |||||||||||
Sponsor Name:Nektar Therapeutics | |||||||||||||
Full Title: A Phase 1/2, Open-label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214, Nivolumab, and Other Anti-Cancer Therapies in Patients with Select Locally Ad... | |||||||||||||
Medical condition: Locally Advanced or Metastatic Solid Tumor Malignancies | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) BE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001359-36 | Sponsor Protocol Number: CA223-001 | Start Date*: 2016-07-26 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase I /II Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (Lirilumab) Administered in Combination with Anti-PD-1 (Nivolumab) in Advanced Refracto... | |||||||||||||
Medical condition: Solid tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) FR (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000038-33 | Sponsor Protocol Number: DF6002-001 | Start Date*: 2021-08-25 |
Sponsor Name:Dragonfly Therapeutics, Inc. | ||
Full Title: A Phase 1/2, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monoth... | ||
Medical condition: Solid Tumor Melanoma NSCLC Triple-negative breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005602-26 | Sponsor Protocol Number: FL-101-2001 | Start Date*: 2021-08-03 | ||||||||||||||||||||||||||
Sponsor Name:Flame Biosciences | ||||||||||||||||||||||||||||
Full Title: A Two-cohort, Phase 2 Study of FL-101 as Neoadjuvant Therapy in Patients with Surgically Resectable Non-Small Cell Lung Cancer | ||||||||||||||||||||||||||||
Medical condition: Surgically resectable non-small cell lung cancer | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: FR (Prematurely Ended) NL (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-004380-40 | Sponsor Protocol Number: CA209-76U | Start Date*: 2020-11-27 | |||||||||||||||||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||||||||||||||||||||||
Full Title: A Phase 1/2 Pharmacokinetic Multi-tumor Study of Subcutaneous Formulation of Ipilimumab Monotherapy and in Combination with Subcutaneous Nivolumab | |||||||||||||||||||||||||||||||||
Medical condition: The study population will include participants diagnosed with metastatic melanoma, advanced/metastatic urothelial carcinoma (mUC), advanced hepatocellular carcinoma (HCC) in Part 1, and metastatic... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
